Article
Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
Cancer chemotherapy and pharmacology - 1 Mar 2017
Mittapalli Rajendar K, Nuthalapati Silpa, Shepherd Stacie Peacock, Xiong Hao
Abstract excerpt
PURPOSE: The objective of the manuscript is to describe the development of a population pharmacokinetic model for ABT-767, a potent and orally bioavailable inhibitor of poly (ADP-ribose) polymerase enzyme, and to evaluate the potential influence of patient demographics and baseline covariates on the pharmacokinetics of ABT-767. METHODS: A total of 1809 plasma ABT-767 concentrations from 90 subjects were used for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.